Here is the design of a clinical trial:

Official Title: Stereotactic-EEG Guided Radio-frequency Thermocoagulation Versus Anterior Temporal Lobectomy for Mesial Temporal Lobe Epilepsy With Hippocampus Sclerosis

Included conditions:
- Epilepsy, Temporal Lobe

Study Armgroups:
- {'label': 'Anterior temporal lobectomy', 'type': 'EXPERIMENTAL', 'description': 'surgical treatment for mTLE', 'interventionNames': ['Procedure: Anterior temporal lobectomy']}
- {'label': 'SEEG guided RF-TC', 'type': 'ACTIVE_COMPARATOR', 'description': 'SEEG recording and minimal invasive treatment for mTLE', 'interventionNames': ['Procedure: SEEG guided RF-TC']}

Interventions:
- {'type': 'PROCEDURE', 'name': 'SEEG guided RF-TC', 'description': 'SEEG implantation after evaluation, record the interictal and ictal EEG, and perform RF-TC after the localization confirmation.', 'armGroupLabels': ['SEEG guided RF-TC']}
- {'type': 'PROCEDURE', 'name': 'Anterior temporal lobectomy', 'description': 'classical surgical treatment for mesial temporal lobe epilepsy, including the resection of neocortex for 5.5cm in non dominant hemisphere or 4.5cm in dominant hemisphere', 'armGroupLabels': ['Anterior temporal lobectomy']}

Primary Outcomes:
- {'measure': 'Cognitive function', 'description': 'Full scaled Wechsler Adult Intelligence Quality IV Chinese edition (WAIS-IV-C), or Wechsler Children Intelligence Quality IV Chinese edition (WCIS-IV-C) Higher values represent a better outcome.', 'timeFrame': '1 year'}

Please estimate the sample size based on the assumption: 
One-sided 95% confidence interval, non-inferiority limit of 10%, expected withdraw rate of 20%.
Sample size
        The sample size was calculated based on our previous experience (cognitive performance decrease of 25% after ATL), similar to findings reported in earlier studies [18]. Approximately 5% of patients exhibited decreased cognitive performance after SEEG-guided RF-TC in our previous series, while most previous studies have reported improvements or a lack of impairment [20â22]. We expect to enrol 20 patients in each arm using a one-sided 95% confidence interval, a non-inferiority limit of 10%, and an expected withdraw rate of 20%. Thus, we aim to include a total of 40 patients in this trial. Patients will be recruited from outpatient and MDT with strict inclusion criteria.
        Participants will be replaced if they withdraw at any time prior to the final follow-up supervised by Dr Yong-Zhi Shan and Guo-Guang Zhao. Those who withdraw from the study during treatment because of specific medical or technical events will also be monitored and replaced. The trial conduct will be audited by the investigators with the whole MDT monthly.